Lescarden Inc. | Balance Sheet

Fiscal year is June-May. All values USD Thousands.
2012
2013
2014
2015
2016
Cash & Short Term Investments
42.60
84.60
10.40
37.20
4.30
Total Accounts Receivable
54.70
26.80
2.10
48.90
1.30
Inventories
104.70
148.40
113.60
83.60
198.00
Total Current Assets
202.00
259.80
126.10
169.70
203.50
Total Assets
202.00
259.80
126.10
169.70
203.50
ST Debt & Current Portion LT Debt
232.00
347.00
-
268.80
278.80
Accounts Payable
257.00
267.30
220.60
172.80
309.40
Other Current Liabilities
25.40
15.30
4.50
-
0.00
Total Current Liabilities
514.40
629.60
225.10
441.60
588.20
Total Liabilities
514.40
629.60
225.10
441.60
588.20
Common Equity (Total)
450.40
371.60
100.80
273.80
386.50
Total Shareholders' Equity
312.40
369.80
99.00
271.90
384.70
Total Equity
312.40
369.80
99.00
271.90
384.70
Liabilities & Shareholders' Equity
202.00
259.80
126.10
169.70
203.50
Preferred Stock (Carrying Value)
138.00
1.80
1.80
1.80
1.80

About Lescarden

View Profile
Address
420 Lexington Avenue
New York New York 10170
United States
Employees -
Website http://www.catrix.com
Updated 07/08/2019
Lescarden, Inc. is a biotechnology company, which engages in the provision of development of natural, biologic therapies for the chronic wound care, dermatology and osteoarthritis markets. It focuses on research and development of biologic materials with focus on wound healing, clinical skin care, osteoarthritis and cancer applications. The company was founded by John Fletcher Prudden in 1960 and is headquartered in New York, NY.